US 11649218
C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
granted A61KA61K31/5513A61K31/553
Quick answer
US patent 11649218 (C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/5513, A61K31/553, A61K31/554, A61P